TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/05/2026
Voltar para busca
Dado oficial do USPTO
MYRIAD GENETICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
61
Atualização mais recente
29/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
42, 44
Data de depósito
21/04/2021
Data de registro
08/08/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/08/2023
Última transação
29/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
04/05/2021
Primeiro uso no comércio
04/05/2021
Código do desenho
3
Tipo de titular
03
Localização do titular
Salt Lake City, UT, US
Examinador
DE JONGE, KATHLEEN
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "MYRIAD" with the "M" appearing as a capital letter formed by four (4) lines that do not touch, and the remainder of the word appearing in lowercase letters, and the word "GENETICS" directly below "MYRIAD" appearing in lowercase letters.
Titulares e representantes
Titulares
Myriad Genetics, Inc.
Representantes
Joyce M. Ferraro Fross Zelnick Lehrman & Zissu, P.C.
Classificação técnica
Classes Nice
Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human geneticsfor scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery servicespharmaceutical research servicespre-clinical medical research screeningclinical trialresearch and evaluation services; biosignaturesgenomicsproteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discoverydrug screening for scientific research purposespre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis servicesevaluation of non-genetic biological response to diseasedrugsthe environment; providing temporary use of non-downloadable computer software for customizingselectingordering health and genetic analysis and diagnostic kits and assays and for accessingviewingstoring health and genetic information via electronicopticalwireless communication networks; scientific research analysis and consulting services which use bioinformatics; gene and tissue bank services that provide DNA samples for use in future medical and scientific researchmedical and scientific educational studies and development of new medical and scientific products and validation thereof
Classe 44
Genetic testing services for diagnostic or treatment purposes; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of geneticsthe identification of genes that predispose individuals to common diseases and health disorders for diagnostic or treatment purposes; medical testingproviding reference and clinical laboratory tests that detectclassifyanalyzeevaluate gene mutationsgene variantsgene expression profilesother molecular abnormalitiesindicatorsmarkers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimensprognosing diseasepredicting disease progression or disease severityidentifying predisposition to developing diseaseevaluating the efficacy or toxicity of medical treatmentsidentifying risk factors of diseasemolecular profiles associated with successful therapies or treatment regimensfor classifying disease progression or severity; medical diagnostic testingmonitoringreporting services; internet-based health care information services; providing an internet website for medical professionals featuring medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical informationproviding medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatmentdrugdosage levels for patients through the use of data obtained through personalized pharmacogenetic testingproteomics and other biological testingindividual behaviors including medication complianceexercise dietsleep patterns and languageepigenetic and environmental factorsbioinformatics analysis and medical and pharmaceutical consultation services related theretodiscussion and interpretation with clients of medical test results and medical analysis related thereto; medical testing servicesproviding medical tests that measureanalyzeinterpret genes and medications of patientsenvironmentalother factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorptiondistributionmetabolismexcretion and each medication's receptor activitymechanism of actionpathways of response and then measures the impact of genomic changes across these pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patientspersonalize medication selectiontreatment options and choices for patientsidentify potentially harmful drug interactionscalculate drug dosage adjustments for patients; and medical information servicespreparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objectiveevidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications
Publicações
Histórico de despachos e eventos da marca no USPTO.
61 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/05/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/05/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/05/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/05/2026
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
02/09/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/07/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/07/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/07/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/07/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/08/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
26/07/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/07/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/07/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/07/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
30/06/2023
EX3G
SOU EXTENSION 3 GRANTED
30/06/2023
IUAF
USE AMENDMENT FILED
27/06/2023
EXT3
SOU EXTENSION 3 FILED
27/06/2023
EEXT
SOU TEAS EXTENSION RECEIVED
27/06/2023
EISU
TEAS STATEMENT OF USE RECEIVED
27/06/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/02/2023
NOAC
CORRECTED NOA E-MAILED
04/02/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
03/02/2023
EX2G
SOU EXTENSION 2 GRANTED
03/02/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
25/01/2023
DRRR
DIVISIONAL REQUEST RECEIVED
15/12/2022
EXT2
SOU EXTENSION 2 FILED
15/12/2022
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
15/12/2022
EEXT
SOU TEAS EXTENSION RECEIVED
15/12/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
27/07/2022
EX1G
SOU EXTENSION 1 GRANTED
25/07/2022
EXT1
SOU EXTENSION 1 FILED
25/07/2022
EEXT
SOU TEAS EXTENSION RECEIVED
25/07/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/06/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/06/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/06/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/06/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/06/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/01/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
27/01/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/01/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/01/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
25/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/11/2021
PUBO
PUBLISHED FOR OPPOSITION
30/11/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/11/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/10/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
25/10/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
25/10/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
25/10/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
25/10/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/09/2021
GNRT
NON-FINAL ACTION E-MAILED
08/09/2021
CNRT
NON-FINAL ACTION WRITTEN
08/09/2021
DOCK
ASSIGNED TO EXAMINER
06/09/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
29/07/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/07/2021
NWAP
NEW APPLICATION ENTERED
24/04/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MYRIAD GENETICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.